The connexin gene family is the most prevalent gene that contributes to hearing loss. Connexins 26 and 30, encoded byGJB2andGJB6, respectively, are the most abundantly expressed connexins in the inner ear. Connexin 43, which is encoded byGJA1, appears to be widely expressed in various organs, including the heart, skin, the brain, and the inner ear. The mutations that arise inGJB2,GJB6, andGJA1can all result in comprehensive or non-comprehensive genetic deafness in newborns. As it is predicted that connexins include at least 20 isoforms in humans, the biosynthesis, structural composition, and degradation of connexins must be precisely regulated so that the gap junctions can properly operate. Certain mutations result in connexins possessing a faulty subcellular localization, failing to transport to the cell membrane and preventing gap junction formation, ultimately leading to connexin dysfunction and hearing loss. In this review, we provide a discussion of the transport models for connexin 43, connexins 30 and 26, mutations affecting trafficking pathways of these connexins, the existing controversies in the trafficking pathways of connexins, and the molecules involved in connexin trafficking and their functions. This review can contribute to a new way of understanding the etiological principles of connexin mutations and finding therapeutic strategies for hereditary deafness.